Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CYCLACEL PHARMACEUTICALS, INC.

(CYCC)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
0.8800 USD   -7.37%
01/06Cyclacel Pharmaceuticals, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
01/05Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
GL
2022Cyclacel Pharmaceuticals, Inc. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CYCLACEL PHARMACEUTICALS, INC. : Other Events (form 8-K)

09/13/2022 | 04:19pm EST
Item 8.01 Other Events.



Declaration of Quarterly Cash Dividend on 6% Convertible Exchangeable Preferred Stock

On September 7, 2022, the Board of Directors (the "Board") of Cyclacel Pharmaceuticals, Inc. (the "Company") declared a quarterly cash dividend in the amount of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock ("Preferred Stock"). The cash dividend will be payable on November 1, 2022 to the holders of record of the Preferred Stock as of the close of business on October 14, 2022.

The Board considered numerous factors in determining whether to declare the quarterly dividend, including the requisite financial analysis and determination of a surplus. While the Board will analyze the advisability of the declaration of dividends in future quarters, there is no assurance that future quarterly dividends will be declared.

© Edgar Online, source Glimpses

All news about CYCLACEL PHARMACEUTICALS, INC.
01/06Cyclacel Pharmaceuticals, Inc. : Notice of Delisting or Failure to Satisfy a Continued Lis..
AQ
01/05Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objective..
GL
2022Cyclacel Pharmaceuticals, Inc. : Change in Directors or Principal Officers, Financial Stat..
AQ
2022Oppenheimer Adjusts Cyclacel Pharmaceuticals Price Target to $10 From $17, Maintains Ou..
MT
2022Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate ..
GL
2022Cyclacel Pharmaceuticals : Declaration of Quarterly Cash Dividend on 6% Convertible Exchan..
PU
2022Cyclacel Pharmaceuticals, Inc. : Other Events (form 8-K)
AQ
2022Cyclacel Pharmaceuticals : November 2022 Corporate Presentation
PU
2022CYCLACEL PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condi..
AQ
2022Transcript : Cyclacel Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 09, 2..
CI
More news
Analyst Recommendations on CYCLACEL PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -21,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,49x
Yield 2022 -
Capitalization 11,0 M 11,0 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 12
Free-Float 93,8%
Chart CYCLACEL PHARMACEUTICALS, INC.
Duration : Period :
Cyclacel Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYCLACEL PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,88 $
Average target price 16,25 $
Spread / Average Target 1 747%
EPS Revisions
Managers and Directors
Spiro Rombotis President, Chief Executive Officer & Director
Paul McBarron Secretary, Chief Operating & Financial Officer
Christopher S. Henney Chairman
Mark Kirschbaum Chief Medical Officer & Senior Vice President
Gregory T. Hradsky Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CYCLACEL PHARMACEUTICALS, INC.31.93%11
VERTEX PHARMACEUTICALS11.31%82 513
REGENERON PHARMACEUTICALS, INC.2.96%79 336
WUXI APPTEC CO., LTD.20.37%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008